Physician profile
Jerome Maxfield
NPI 1528129376
$2,500.25
in general payments reported to CMS, 2019-2025
23 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $423 · 2023: $233 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.53 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $432.64 | 2022-2025 | Reblozyl, Opdivo |
| Incyte Corporation | $222.23 | 2025 | Zynyz |
| Astrazeneca Pharmaceuticals LP | $214.82 | 2025 | Calquence |
| Beone Medicines USA, INC. | $150.00 | 2025 | Brukinsa |
| Kite Pharma, INC. | $146.26 | 2025 | Yescarta |
| Daiichi Sankyo INC. | $144.80 | 2021-2025 | Enhertu |
| Seagen INC. | $141.76 | 2021-2023 | Adcetris |
| Astellas Pharma Global Development | $125.92 | 2025 | Padcev |
| Dova Pharmaceuticals | $125.00 | 2021 | |
| Abbvie INC. | $123.00 | 2025 | |
| Boston Scientific Corporation | $109.99 | 2022 | |
| Astellas Pharma US INC | $99.00 | 2022 | |
| Puma Biotechnology, INC. | $82.00 | 2025 | |
| Medtronic, INC. | $81.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.45 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $55.53 | 2025 | Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $35.41 | 2025 | Fruzaqla |
| Tersera Therapeutics LLC | $27.85 | 2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $25.44 | 2025 | Onivyde |
| Genmab U.S., INC. | $23.48 | 2025 | Epkinly |
| Merck Sharp & Dohme LLC | $21.19 | 2025 | Welireg, Keytruda |
| Array Biopharma INC | $19.27 | 2025 | Mektovi, Elrexfio, Braftovi |
| Deciphera Pharmaceuticals INC. | $15.69 | 2025 | Qinlock, Romvimza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Maxfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.